US4666895A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Diphosphonic acid derivatives
Assignee: Roche Diagnostics GmbH
•
Filing: 1986-03-31
•
Granted: 1987-05-19
•
Expires: 2006-03-31
Abstract
Abstract The present invention provides diphosphonic acid derivatives of the general formula: <IMAGE> (I) wherein R1, R2, R3, R4 and R5, independently of one another or also together, signify hydrogen atoms or lower alkyl radicals, whereby R1 and X or R3 and Y or R4 and Z, together with the nitrogen atom to which they are attached, can form a five- or six-membered ring, X and Y, which can be the same or different, represent a straight-chained or branched alkylene chain with up to 6 carbon atoms which can optionally be substituted by aromatic or heteroaromatic radicals, Z is a straight-chained or branched alkylene chain with up to 6 carbon atoms, which can be interrupted by heteroatoms and can optionally also be substituted by aromatic or heteroaromatic radicals, n is 0, 1 or 2 and A is a hydrogen atom or a hydroxyl group, and the pharmacologically acceptable salts thereof. The present invention also provides processes for the preparation of these new diphosphonic acid derivatives and pharmaceutical compositions containing them for the treatment of calcium metabolism disturbances.
Inventors
- 👤 Elmar Bosies
- 👤 Rudi Gall
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 18:38
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/06; C07K5/06191; A; A61; A61P; A61P3/00; A61P3/02; A61P3/12; A61P3/14; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3839; C07F9/3873; C07F9/40; C07F9/4003; C07F9/4025; C07F9/405; C07K5/08; C07K5/0827; A61K; A61K38/00
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
161 words
A diphosphonic acid derivative compound of the formula ##STR12## wherein R 1 , R 2 , R 3 , R 4 and R 5 , are individually selected from the group consisting of hydrogen and C 1 -C 4 lower alkyl. R 1 and X or R 3 and Y or R 4 and Z, together with the nitrogen atom to which they are attached, can form a five-or six-membered ring, X and Y, which can be the same or different, represent a straight- or branched alkylene chain with up to 6 carbon atoms which is unsubstituted or is substituted once by phenyl, imidazolyl or indolyl, Z is a straight-chained or branched alkylene chain with up to 6 carbon atoms and which is uninterrupted or interrupted once by Oxygen or sulphur and which is unsubstituted or substituted once by phenyl, imidazolyl or indolyl, n is 0, 1 or 2 and A is hydrogen or hydroxyl, or a pharmacologically acceptable salt thereof.
Claim 2
Dependent Claim
161 words
A diphosphonic acid derivative compound of the formula ##STR12## wherein R 1 , R 2 , R 3 , R 4 and R 5 , are individually selected from the group consisting of hydrogen and C 1 -C 4 lower alkyl. R 1 and X or R 3 and Y or R 4 and Z, together with the nitrogen atom to which they are attached, can form a five-or six-membered ring, X and Y, which can be the same or different, represent a straight- or branched alkylene chain with up to 6 carbon atoms which is unsubstituted or is substituted once by phenyl, imidazolyl or indolyl, Z is a straight-chained or branched alkylene chain with up to 6 carbon atoms and which is uninterrupted or interrupted once by Oxygen or sulphur and which is unsubstituted or substituted once by phenyl, imidazolyl or indolyl, n is 0, 1 or 2 and A is hydrogen or hydroxyl, or a pharmacologically acceptable salt thereof.
Claim 3
Dependent Claim
54 words
The compound of claim 1, wherein A is hydroxyl, n is 0 or 1, R 4 and R 5 are hydrogen, Z is a straight-chained alkylene chain with 2 to 5 carbon atoms, the grouping (R 1 ,R 2 )--N--X--CO--is glycyl, alanyl, prolyl or sarcosyl and the grouping --N(R 3 )--Y--CO--is glycyl or alanyl.
Claim 4
Dependent Claim
37 words
The compound of claim 1 wherein the substituents for X,Y and Z are individually selected from the group consisting of phenyl, imidazolyl and indolyl, and Z is a straight-chained alkylene chain with up to 6 carbon atoms.
Claim 5
Dependent Claim
35 words
The compound of claim 3 wherein R 1 , R 2 , R 3 and R 4 are individually selected from the group consisting of hydrogen, methyl, ethyl and isopropyl, and R 5 is hydrogen.
Claim 6
Dependent Claim
35 words
The compound of claim 1 wherein R 1 , R 2 , R 3 and R 4 are individually selected from the group consisting of hydrogen, methyl, ethyl and isopropyl, and R 5 is hydrogen.
Claim 7
Dependent Claim
15 words
The compound of claim 1 designated 4-(N-L-alanyl)-aminobutane-1-hydroxy-1,1-diphosphonic acid or the mono- or disodium salt thereof.
Claim 8
Dependent Claim
16 words
The compound of claim 1 designated 5-(N-D,L-alanyl)-aminopentane-1-hydroxy-1, 1-diphosphonic acid or the mono- or disodium salt thereof.
Claim 9
Dependent Claim
18 words
The compound of claim 1 designated 5-(N- , L-alanyl)-aminopentane-1-hydroxy-1, 1-diphosphonic acid or the mono- or disodium salt thereof.
Claim 10
Dependent Claim
15 words
The compound of claim 1 designated 4-(N-sarcosyl)-aminobutane-1-hydroxy-1, 1-diphosphonic acid the mono- or disodium salt thereof.
Claim 11
Dependent Claim
19 words
The compound of claim 1 in the form of a mono- or dialkali metal salt or a ammonium salt.
Claim 12
Dependent Claim
24 words
A pharmaceutical composition for treatment of calcium metabolism disturbances comprising an effective amount of the compound of claim 1 in a pharmaceutically acceptable carrier.
Claim 13
Dependent Claim
17 words
The pharmaceutical composition of claim 11 containing 1 to 1000 mg of the compound of claim 1.
Claim 14
Dependent Claim
55 words
The pharmaceutical composition of claim 11 wherein the compound is 4-(N- L-alanyl)-aminobutane -1-hydroxy-1, 1-diphosphonic acid or the mono- or disodium salt thereof or 5-(N-D, L-alanyl)-aminopentane-1-hydroxy-1, 1-diphosphonic acid or the mono- or disodium salt thereof or 5-(N-L-alanyl)-aminopentane-1-hydroxy-1, 1-diphosphonic acid or the mono- or disodium salt thereof or 4-(N-sarcosyl)-aminobutane-1-hydroxy-1, 1-diphosphonic acid the mono- or disodium salt thereof.
Claim 15
Dependent Claim
20 words
A method for the treatment of calcium metabolism disturbances comprising administering an effective amount of the compound of claim 1.
Claim 16
Dependent Claim
15 words
The method of claim 14 wherein 1 to 1000 mg of the compound are administered.
Claim 17
Dependent Claim
15 words
The method of claim 15 wherein 10 to 200 mg of the compound are administered.
Claim 18
Dependent Claim
15 words
The method of claim 15 wherein 1 to 100 mg of the compound are administered.
Claim 19
Dependent Claim
21 words
A method for the treatment of calcium metabolism disturbances comprising administering an effective amount of the pharmaceutical composition of claim 13.
References Cited (Backward Citations)
US3979385A
Cited
US3899496A
Cited
US4134969A
Cited
US4029697A
Cited
US4239695A
Cited
EP0000061A1
Cited
US4503049A
Cited
GB2118042A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-18 | 1990-11-17 | 1991-05-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-18 | 1994-11-17 | 1995-05-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-18 | 1998-11-17 | 1999-05-19 | $7700.00 | Window Closed / Lapsed |